Actinium Pharmaceuticals, Inc. (ATNM): Sloan-kettering Cance Memorial , 10% owner of Actinium Pharmaceuticals, Inc. sold 40,068 shares on May 26, 2016. The Insider selling transaction was reported by the company on May 31, 2016 to the Securities and Exchange Commission. The shares were sold at $1.93 per share for a total value of $77,060.56 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 26, 2016, Sloan-kettering Cance Memorial (10% owner) sold 36,400 shares at $1.91 per share price.On Apr 18, 2016, C. David Nicholson, (director) purchased 5,000 shares at $2.00 per share price.Also, On Apr 18, 2016, Sergio Traversa (director) purchased 3,000 shares at $2.02 per share price.On Apr 18, 2016, Sandesh Seth (director other) purchased 15,000 shares at $2.00 per share price.
Shares of Actinium Pharmaceuticals Inc (ATNM) ended Friday, May 27, 2016 session in red amid volatile trading. The shares closed down -0.06 points or -3.16% at $1.84 with 91,161 shares getting traded. Post opening the session at $1.91, the shares hit an intraday low of $1.8201 and an intraday high of $1.9175 and the price vacillated in this range throughout the day. The company has a market cap of $86 M and the number of outstanding shares has been calculated to be 4,69,50,180 shares. The 52-week high of Actinium Pharmaceuticals Inc is $4.1 and the 52-week low is $1.52.
Actinium Pharmaceuticals Inc. (Actinium) is a biopharmaceutical company engaged in developing therapies for diseases using its alpha particle immunotherapy (APIT) platform and other related technologies. The Company’s products include Actimab-A an antibody-drug construct containing actinium 225 (Ac-225) and Iomab-B an antibody-drug construct containing iodine 131 (I-131). As of December 31 2014 Actinium’s Actimab-A was in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. As of December 31 2014 the Company had four product candidates in clinical trials: Actimab-A (HuM195-Ac-225) Iomab-B (BC8-I-131) BC8-Y-90 and BC8-SA. As of December 31 2014 BC8-Y-90 and BC8-SA were in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center (FHCRC).